FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

What happened: The FDA is requiring all GLP-1 medications to include information about the potential risk of NAION, a rare eye condition that could lead to sudden and permanent blindness, on warning labels. Key numbers: The requirement covers all GLP-1 medications, including Novo Nordisk's Ozempic and Wegovy, Eli Lilly's Mounjaro and Zepbound, and Sanofi's Soliqua. Why it matters: The label change applies across the GLP-1 class, affecting products from Novo Nordisk, Eli Lilly, and Sanofi. Coverage: 6 outlets in 24h

The FDA is requiring all GLP-1 medications to include information about the potential risk of NAION, a rare eye condition that could lead to sudden and permanent blindness, on warning labels.

The label change applies across the GLP-1 class, affecting products from Novo Nordisk, Eli Lilly, and Sanofi.